

IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES

Publication number: JP2001518930 (T)

Publication date: 2001-10-16

Inventor(s):

Applicant(s):

Classification:

- international: **A61K51/00; A61K39/395; A61P35/00; A61P43/00; C07K16/28; A61K38/00; A61K51/00; A61K39/395; A61P35/00; A61P43/00; C07K16/18; A61K38/00; (IPC1-7): A61K39/395; A61K51/00; A61P35/00; A61P43/00**

- European: C07K16/28A; A61K39/395C3

Application number: JP19980545761T 19980317

Priority number(s): US19970041506P 19970324; WO1998US05075 19980317

Also published as:

 WO9842378 (A1)
 ZA9802438 (A)
 IN189313 (A1)
 ES2241129 (T3)
 EP0969866 (A1)

more >>

Abstract not available for JP 2001518930 (T)

Abstract of corresponding document: **WO 9842378 (A1)**

B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Data supplied from the **esp@cenet** database — Worldwide